Company name Diplomat Pharmacy, Inc.
Stock symbol DPLO
Status Under Investigation

NEW YORK, December 11, 2019 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Diplomat Pharmacy, Inc. (NYSE: DPLO) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed sale to UnitedHealth Group Inc.

On December 9, 2019, Diplomat announced that it had signed an agreement to be acquired by Merck for $4 in cash, or a total of approximately $300 million. The deal is scheduled to close in early 2020.

Bragar Eagel & Squire is concerned that Diplomat’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Indeed, Diplomat’s stock has recently traded well above the $4 per share deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Diplomat stockholders.

First name*

Last name*

City, state, ZIP code

Email address*

Daytime phone

Evening phone

Purchase Date

No. of Shares

Purchase Price

Purchase Date

No. of Shares

Purchase Price

Join action?
YesNo


Call to provide more information: Tel: (212) 355-4648

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.